Vaxil Bio

Vaxil Bio EBITDA per Share

EBITDA per Share of Vaxil Bio (VXL.V) as of Oct 17, 2026.

EBITDA per Share

-0.00CAD

YoY

20.95%

Last updated:

EBITDA per Share of Vaxil Bio is 2025 -0.00 CAD. EBITDA per Share of Vaxil Bio was 2024 -0.00 CAD. It decreases by 20.95% lower compared to the previous year.

The Vaxil Bio EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.01 CAD
Jan 1, 2019
-0.01 CAD
Jan 1, 2020
-0.01 CAD
Jan 1, 2021
-0.01 CAD
Jan 1, 2022
-0.00 CAD
Jan 1, 2023
-0.00 CAD
Jan 1, 2024
-0.00 CAD
Jan 1, 2025
-0.00 CAD
The Vaxil Bio EBITDA per Share history
YEAREBITDA per ShareYoY
-0.00CAD+20.95%
-0.00CAD+58,167.29%
-0.00CAD-99.96%
-0.00CAD-39.44%
-0.01CAD-43.56%
-0.01CAD+5.99%
-0.01CAD+5.07%
-0.01CAD-67.94%
-0.03CAD-63.86%
-0.10CAD-31.54%
-0.14CAD+43,789.35%
-0.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vaxil Bio Stock analysis

What does Vaxil Bio do? Vaxil Bio Ltd is a biotechnology company based in Toronto, Canada, specializing in immunotherapy for cancer and infectious diseases. Listed on March 2, 2011, the firm develops novel treatments using a platform based on signal peptides. Its advanced product, ImMucin, is a vaccine derived from MUC1 signal peptides that completed Phase I/II trials for multiple myeloma. The company also holds candidates for COVID-19 and tuberculosis vaccines, as well as monoclonal antibodies for oncology and infectious diseases. Additionally, Vaxil Bio has initiated a pre-clinical program for a drug delivery polymer targeting E-selectin, licensed from BGN Technologies, aiming to create targeted therapies against critical disease targets. Vaxil Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vaxil Bio stock

On Eulerpool you can find the complete historical development of EBITDA per Share Vaxil Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Vaxil Bio

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Vaxil Bio